Skip to main content

Cancer Genetics Partners With ApoCell to Offer its ApoStream to Biotech, Pharma Companies

NEW YORK (GenomeWeb) – Cancer Genetics announced today that it has agreed to work with MD Anderson spinout ApoCell to make its ApoStream liquid biopsy technology available to biotech and pharmaceutical companies.

ApoStream is a platform for the detection, isolation, and capture of circulating tumor cells (or other rare cells), and does not require the use of labels or antibodies.

According to the new partners, ApoStream has already been integrated into over 35 clinical trials, including studies of prostate, lung, breast, colon, pancreatic and renal cancers. Under the terms of their new collaboration, ApoCell and Cancer Genetics will continue to advance evaluations of the platform in trials of both targeted therapies and immunotherapies, and will also study other new applications, such as monitoring patients for emerging drug resistance.

The new partnership includes "immediate plans" on the part of Cancer Genetics to provide the platform to its customers for discovery, clinical trial, and patient monitoring applications. The companies also said that they have already initiated joint projects coupling ApoStream with Cancer Genetics' disease-specific molecular profiling.